ArticleProbiotics and antimicrobial proteins2026
Engineered Phytoene-Producing Saccharomyces cerevisiae Alleviates Cyclophosphamide-Induced Intestinal Barrier Dysfunction and Gut Dysbiosis.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intestinal mucosal barrier dysfunction is a critical driver of various gastrointestinal disorders, typically manifesting as physicochemical barrier disruption, immune dysregulation, and microbial dysbiosis. Harnessing the potent antioxidant properties and high intestinal bioavailability of phytoene, alongside the suitability of Saccharomyces cerevisiae as a food-grade expression host, we evaluated the efficacy of engineered phytoene-producing S. cerevisiae (PSc) in attenuating cyclophosphamide (CP)-induced jejunal mucosal damage in mice. Single-dose oral retention assays revealed that PSc preserved viability during gastric transit and transiently colonized the intestine for over 24 h. Dietary supplementation with PSc effectively mitigated CP-induced jejunal injury and reversed the pathological atrophy in lymphoid organs, specifically the spleen and thymus. Mechanistically, PSc restored the mucus barrier by augmenting goblet cell counts and MUC2 expression, reinforced epithelial integrity by upregulating tight junction proteins, and fortified the immunological barrier by modulating the secretion of sIgA and cytokines (e.g., IL-1β, IL-6, TNF-α, and TGF-β3). Furthermore, PSc remodeled both gut bacterial and fungal communities, enriching beneficial taxa such as Muribaculaceae, Lachnospiraceae, and Kazachstania while suppressing pathogenic microbes, thereby restoring microbial homeostasis and facilitating mucosal repair. In conclusion, this study demonstrates that PSc ameliorated CP-induced intestinal injury by restoring multi-layered barrier functions, establishing a robust rationale for its development as a novel probiotic and functional food supplement for managing chemotherapy-induced intestinal complications.
Indexed as
Identifiers
42622793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.